kah6imi9xy
Dołączył: 22 Lis 2010
Posty: 175
Przeczytał: 0 tematów
Ostrzeżeń: 0/5
Skąd: England
|
 Wysłany: Pon 8:27, 20 Gru 2010 Temat postu: Puma Fluxion II Aarkstore Enterprise - Puma Footwe |
 |
|
The main concerns for outsourcing clinical trials to CROs
Which current or future therapies that will drive the market for clinical trial business from 2008 to 2018
Relatively thin pipeline.
Because of the nature of the clinical trials industry it will [link widoczny dla zalogowanych], in turn, experience increasing pressures to deliver a cost-effective service. The demand among drugs companies for a more cost-efficient pipeline has therefore intensified in recent years. The strategy that pharmaceutical companies now seem to be applying to clinical trials mirrors the latest trends in the drug discovery section of development.
Contract research organisations (CROs) are playing increasingly vital roles on behalf of manufacturers in the global drug development process, from conducting Phase I trials to post-marketing studies. It is often difficult for pharmaceutical and biotech companies to decide which CRO to offer a contract to. However, the market is due to undergo rapid change over the coming years, with different companies approaching the challenges in different ways. The CRO market, however, continues to grow steadily at an average 10% yearly growth rate. ...predicts that there remains a sufficient growth opportunity for both mainstream and other CROs.
Why You Should Buy This Report :
In Global Clinical Trial Business 2008-2018 you will receive the following essential information for understanding the clinical trial business:
Existing generic competition
bal Clinical Trial Business Report & Analysis 2008-2018 Jul 2008
The global clinical trials business is worth an estimated $50bn in 2008, with a growth of rate of 10%. The market will show considerable growth in the future, as this visiongain report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the nature of clinical trials has changed considerably. An increased emphasis has been placed on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain the high output of recent years. Consequently, the pharmaceutical industry has witnessed rapid expansion of outsourced clinical services in both the West and in developing nations, most notably India and China. Importantly, pharmaceutical and biotechnological companies are increasingly delegating the responsibility of clinical trials to contract research organisations (CROs).
This visiongain report investigates the global market for such services, providing forecasts for revenues and expenditure there [link widoczny dla zalogowanych], as well as a comprehensive examination of principles driving and restraining the clinical trials market worldwide. Neither pharmaceutical companies nor CROs can afford to ignore this research [link widoczny dla zalogowanych], which relies heavily upon interviews with experts in the relevant sectors, as well as providing comprehensive revenue forecasts for the next 10 years.
The majority of the revenues generated by the clinical trials industry are due to large pharmaceutical companies outsourcing clinical research, the most crucial and expensive stage of drug development, to companies specialising in that work. The major challenge for the pharmaceutical companies in the next five years will be to maintain high growth rates. The branded pharmaceuticals market is under substantial pressure due to:
The value of the clinical trial business market and its principal market segments from 2008 to 2018
Market drivers and restraints, including a comprehensive SWOT analysis
Ways to improve cost-effectiveness of clinical tria
The present state of clinical trial business and future trends there
The companies involved in clinical trial business and their business strategy
Comprehensive views of key opinion leaders on clinical trial business
What contract research opportunities exist for market entrants, both established companies and newcomers
Forecasts for revenue in each of the phases of clinical trial business
Impending loss of major patents
相关的主题文章：
[link widoczny dla zalogowanych]
Puma Classic Barefoot Vibram Fivefingers Puma Clyd
[link widoczny dla zalogowanych]
Post został pochwalony 0 razy
|
|
